试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Safety and Tolerability of AC01 in patients with heart failureMedDRA version: 20.0Level: LLTClassification code: 10078289Term: Heart failure with reduced ejection fraction Class: 10007541Heart FailureCTIS2022-500347-20-00Anacardio AB116
进行中（未招募）
1 期
A first-in-human clinical study to assess safety and tolerability of genetically modified T-cells in ROR1 positive tumorsChronic lymphocytic leukemia, Adrenocortical carcinoma, Breast cancer, Mantle cell lymphoma, Ovarian cancerMedDRA version: 20.0Level: PTClassification code: 10001388Term: Adrenocortical carcinoma Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10006187Term: Breast cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10061275Term: Mantle cell lymphoma Class: 100000004864CTIS2024-512019-36-00niversitaetsklinikum Wuerzburg AöR46
进行中（未招募）
1 期
A trial to investigate the effect of acalabrutinib on skin prick test wheal size in adults with grass pollen allergyCTIS2023-505783-11-00Alk-Abello A/S12
进行中（未招募）
1 期
A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOADCTIS2023-508363-79-00Alnylam Pharmaceuticals Inc.59
招募中
1 期
Study of SGN-PDL1V in Advanced Solid TumorsCTIS2023-506604-18-00Seagen Inc.322